![](https://ml.globenewswire.com/media/9c96f1a7-e104-47d4-8011-8c19496681c2/small/final-veruinclogo-rgb-300dpi-jpg.jpg)
Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to ...
MIAMI, FL, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute …